The many faces of lung cancer requires an appreciation of nuance in treatment
Barcelona – Many observers seem to so be single mindedly focused on immunotherapies of late that they may well be forgiven that, hey, there’s still much going on the world of targeted therapies!
If there is one thing we can learn from the lung cancer (and CML) communities it is their dedication to identifying resistance mechanisms and along with them, novel targets for subsequent therapy in order to set about improving outcomes for people with the disease.
As a result, lung cancer can now be segmented into many subsets, each requiring careful consideration of appropriate therapy options, not only in newly diagnosed disease, but also what to do with subsequent lines of therapy.
In this review, our third from the WCLC 2019 meeting, we pull together a lot of disparate loose ends on targeted therapies and draw some important themes together…
To learn more from our latest oncology conference insights and get a heads up on the evolving science and resistance mechanisms, subscribers can log-in or you can click to gain access to BSB Premium Content.
A rare dry spell in Barcelona as the clouds roll in bringing yet more rain
Barcelona – While the weather for the World Congress on Lung Cancer (WCLC) has been largely gloomy with plenty of rainy spells, there’s much good news to report on the clinical front.
After yesterday’s review of the Amgen KRAS inhibitor data in G12C mutation positive patients receiving AMG 510, it’s now time to turn our attention to immunotherapy developments with several important trial readouts and in-depth analyses to discuss.
We will be posting a separate summary of the key highlights on targeted therapy, but first let’s consider what we learned on the immunotherapy front, including some of the science behind it all…
To learn more from our latest oncology conference insights and get a heads up on the details, subscribers can log-in or you can click to gain access to BSB Premium Content.